Phosphoinositide 3-kinase in Health and Disease pp 241-262

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 347)

New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)

Chapter

Abstract

mTOR (mammalian Target of Rapamycin) is the hub of the phosphoinositide 3-Kinase (PI3-K)→Akt→mTOR pathway, which is one of the most commonly mutated pathways in cancer. PI3-Ks and mTOR are related kinases which share an evolutionarily related kinase domain, although the former is a lipid kinase and the latter is a protein kinase. As a result of their similar ATP sites, the prototypical PI3-K inhibitors LY294002 and wortmannin inhibit both kinases, although the compounds have been primarily thought of as inhibitors of PI3-Ks. The widespread use of these reagents to understand PI3-K signaling and the likelihood that many of their effects are confounded by dual inhibition of PI3-K and mTOR make it essential to develop selective mTOR inhibitors in part to understand the unique cellular effects of inhibition of this key downstream component in the growth factor pathway. Rapamycin has historically provided a means for selective mTOR inhibition, yet it is not a typical ATP competitive inhibitor, making its effects difficult to reconcile with LY294002 and wortmannin. Several groups have recently reported pharmacological agents which inhibit mTOR but not PI3-K, providing a new pharmacological approach to selective mTOR inhibition. The TOR kinase domain inhibitors of mTOR have been termed TORKinibs to distinguish their mode of action from rapamycin and its analogs (rapalogs). These inhibitors bind to the ATP binding site of the kinase domain of mTOR and as a result inhibit both mTOR complexes, TORC1 (rapamycin sensitive) and TORC2 (rapamycin resistant). These molecules have allowed a reinvestigation of mTOR and in particular a reinvestigation of the mechanistic basis for incomplete proliferative arrest of cells by Rapamycin. A consensus has quickly emerged from the study of various TORKinibs that Rapamycin is ineffective at blocking cell proliferation because it only partially inhibits the activity of mTORC1. The profound anti-proliferative effect of TORKinibs suggests that as the molecules enter the clinic they may be successful in the treatment of cancers where rapamycin has failed.

References

  1. Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14:483–510PubMedCrossRefGoogle Scholar
  2. Andjelkovic M et al (1997) Role of translocation in the activation and function of protein kinase B. J Biol Chem 272(50):31515–31524PubMedCrossRefGoogle Scholar
  3. Apsel B et al (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 4(11):691–699PubMedCrossRefGoogle Scholar
  4. Brown EJ et al (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369(6483):756–758PubMedCrossRefGoogle Scholar
  5. Brunn GJ et al (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. Embo J 15(19):5256–5267PubMedGoogle Scholar
  6. Brunn GJ et al (1997) Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277(5322):99–101PubMedCrossRefGoogle Scholar
  7. Burnett PE et al (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95(4):1432–1437PubMedCrossRefGoogle Scholar
  8. Cafferkey R et al (1993) Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol 13(10):6012–6023PubMedGoogle Scholar
  9. Carracedo A et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9):3065–3074PubMedGoogle Scholar
  10. Chan TO, Tsichlis PN (2001) PDK2: a complex tail in one Akt. Sci STKE 2001(66):PE1PubMedCrossRefGoogle Scholar
  11. Chen Y et al (1994) A putative sirolimus (rapamycin) effector protein. Biochem Biophys Res Commun 203(1):1–7PubMedCrossRefGoogle Scholar
  12. Chiu MI, Katz H, Berlin V (1994) RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 91(26):12574–12578PubMedCrossRefGoogle Scholar
  13. Chresta CM et al (2010) AZD8055 is a potent, selective and orally bioavailable ATP-Competitive mTOR kinase inhibitor with in vitro and in vivo anti-tumor activity. Cancer Res 70(1):288–298CrossRefGoogle Scholar
  14. Collins BJ et al (2003) In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. Embo J 22(16):4202–4211PubMedCrossRefGoogle Scholar
  15. Facchinetti V et al (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. Embo J 27(14):1932–1943PubMedCrossRefGoogle Scholar
  16. Fan QW et al (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5):341–349PubMedCrossRefGoogle Scholar
  17. Fang Y et al (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294(5548):1942–1945PubMedCrossRefGoogle Scholar
  18. Feldman ME et al (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7(2):e38PubMedCrossRefGoogle Scholar
  19. Folkes AJ et al (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51(18):5522–5532PubMedCrossRefGoogle Scholar
  20. Foster DA (2007) Regulation of mTOR by phosphatidic acid? Cancer Res 67(1):1–4PubMedCrossRefGoogle Scholar
  21. Garcia-Martinez JM, Alessi DR (2008) mTOR complex-2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum and glucocorticoid induced protein kinase-1 (SGK1). Biochem J 416(3):375–385CrossRefGoogle Scholar
  22. Garcia-Martinez JM et al (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421(1):29–42PubMedCrossRefGoogle Scholar
  23. Gingras AC et al (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13(11):1422–1437PubMedCrossRefGoogle Scholar
  24. Gingras AC et al (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15(21):2852–2864PubMedGoogle Scholar
  25. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12(1):9–22PubMedCrossRefGoogle Scholar
  26. Guertin DA et al (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11(6):859–871PubMedCrossRefGoogle Scholar
  27. Guertin DA et al (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15(2):148–159PubMedCrossRefGoogle Scholar
  28. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRefGoogle Scholar
  29. Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253(5022):905–909PubMedCrossRefGoogle Scholar
  30. Helliwell SB et al (1994) TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell 5(1):105–118PubMedGoogle Scholar
  31. Hresko RC, Mueckler M (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280(49):40406–40416PubMedCrossRefGoogle Scholar
  32. Ikenoue T et al (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. Embo J 27(14):1919–1931PubMedCrossRefGoogle Scholar
  33. Inoki K, Guan KL (2009) Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet 18(R1):R94–100PubMedCrossRefGoogle Scholar
  34. Jacinto E, Lorberg A (2008) TOR regulation of AGC kinases in yeast and mammals. Biochem J 410(1):19–37PubMedCrossRefGoogle Scholar
  35. Jacinto E et al (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127(1):125–137PubMedCrossRefGoogle Scholar
  36. Kannan N et al (2007) The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci USA 104(4):1272–1277PubMedCrossRefGoogle Scholar
  37. Kim DH et al (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110(2):163–175PubMedCrossRefGoogle Scholar
  38. Kinkade CW et al (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118(9):3051–3064PubMedGoogle Scholar
  39. Knight ZA, Shokat KM (2005) Features of selective kinase inhibitors. Chem Biol 12(6):621–637PubMedCrossRefGoogle Scholar
  40. Knight ZA et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125(4):733–747PubMedCrossRefGoogle Scholar
  41. Kumar A et al (2008) Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol 28(1):61–70PubMedCrossRefGoogle Scholar
  42. Kunz J et al (1993) Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73(3):585–596PubMedCrossRefGoogle Scholar
  43. Li J et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947PubMedCrossRefGoogle Scholar
  44. Loewith R et al (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10(3):457–468PubMedCrossRefGoogle Scholar
  45. Maira SM et al (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7(7):1851–1863PubMedCrossRefGoogle Scholar
  46. Manning BD et al (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19(15):1773–1778PubMedCrossRefGoogle Scholar
  47. Nowak P et al (2009) Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase. J Med Chem 52(22):7081–7089CrossRefGoogle Scholar
  48. Okuzumi T et al (2009) Inhibitor hijacking of Akt activation. Nat Chem Biol 5(7):484–493PubMedCrossRefGoogle Scholar
  49. Pearson RB et al (1995) The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. Embo J 14(21):5279–5287PubMedGoogle Scholar
  50. Raynaud FI et al (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8(7):1725–1738PubMedCrossRefGoogle Scholar
  51. Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433(7025):477–480PubMedCrossRefGoogle Scholar
  52. Rini B, Kar S, Kirkpatrick P (2007) Temsirolimus. Nat Rev Drug Discov 6(8):599–600CrossRefGoogle Scholar
  53. Ruggero D, Pandolfi PP (2003) Does the ribosome translate cancer? Nat Rev Cancer 3(3):179–92PubMedCrossRefGoogle Scholar
  54. Ruggero D, Sonenberg N (2005) The Akt of translational control. Oncogene 24(50):7426–7434PubMedCrossRefGoogle Scholar
  55. Ruggero D et al (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10(5):484–486PubMedCrossRefGoogle Scholar
  56. Sabatini DM et al (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78(1):35–43PubMedCrossRefGoogle Scholar
  57. Sabers CJ et al (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270(2):815–822PubMedCrossRefGoogle Scholar
  58. Samuels Y et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554PubMedCrossRefGoogle Scholar
  59. Sarbassov DD et al (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14(14):1296–1302PubMedCrossRefGoogle Scholar
  60. Sarbassov DD et al (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101PubMedCrossRefGoogle Scholar
  61. Sarbassov DD et al (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22(2):159–168PubMedCrossRefGoogle Scholar
  62. Sedrani R et al (1998) Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 30(5):2192–2194PubMedCrossRefGoogle Scholar
  63. Shiota C et al (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11(4):583–589PubMedCrossRefGoogle Scholar
  64. Shor B et al (2008) A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 68(8):2934–2943PubMedCrossRefGoogle Scholar
  65. Sonenberg N, Hershey JWB, Mathews M (2000) Translational control of gene expression, 2nd edn. Cold Spring Harbor monograph series, vol 39. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 1020Google Scholar
  66. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7(2):85–96PubMedCrossRefGoogle Scholar
  67. Thoreen CC et al (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284(12):8023–8032PubMedCrossRefGoogle Scholar
  68. Veverka V et al (2008) Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 27(5):585–595PubMedCrossRefGoogle Scholar
  69. Vlahos CJ et al (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269(7):5241–5248PubMedGoogle Scholar
  70. Walker EH et al (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6(4):909–919PubMedCrossRefGoogle Scholar
  71. Wan X et al (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940PubMedCrossRefGoogle Scholar
  72. Wang X et al (2005) Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol 25(7):2558–2572PubMedCrossRefGoogle Scholar
  73. Yang J et al (2002) Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 9(12):940–944PubMedCrossRefGoogle Scholar
  74. Yu K et al (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 69(15):6232–6240PubMedCrossRefGoogle Scholar
  75. Zask A et al 2009 ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J Med Chem 52(16):5013–5016PubMedCrossRefGoogle Scholar
  76. Zheng XF et al (1995) TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82(1):121–130PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Howard Hughes Medical Institute and Department of Cellular and Molecular PharmacologyUC San FranciscoSan FranciscoUSA

Personalised recommendations